Pharmacotherapy is an important component of treatment for children and adolescents with bipolar disorder. The body of evidence supporting safe and effective treatments in this population is growing. Available data provide information on the risks and benefits of pharmacologic agents used for acute manic, mixed, and depressive episodes as well as for maintenance treatment. Lithium, anticonvulsants, and antipsychotics comprise the armamentarium for treating pediatric bipolar disorder. When selecting treatment, clinicians must consider the efficacy and side effect profile of potential pharmacotherapies, as well as the patient’s history, including the presence of comorbidities, in order to develop a treatment plan that will ensure optimal outcomes.
Supplement Article September 15, 2016
Evidence-Based Pharmacologic Treatment of Pediatric Bipolar Disorder
J Clin Psychiatry 2016;77(suppl E1):e02
Article Abstract
Vol 86 • 2025 • Number 2
Read the Current Issue
Original Research
Incidence and Risk Factors for Suicide Attempt During Pregnancy and Postpartum
Original Research
Valbenazine in Elderly Adults With Tardive Dyskinesia
Academic Highlights
Optimizing Treatment With Aripiprazole Monohydrate: Pharmacokinetic Advantages of Long-Acting Injectable Formulations, A Consensus Panel Report
Original Research
Older Adults Visiting Emergency Departments for Mental Health Issues:A CHIRPP Database Study
Consensus Statement
Developing a Treatment-Resistant Depression Consultation Program, Part I: Practical and Logistical Considerations
Brief Report